-
Data published today describes positive interim results from the LuPIN trial Veyonda? (NOX66) dose-finding study
-
69% combined PSA response rate is higher than that observed in studies of 177Lu-PSMA-617 alone
-
75% of men treated with Veyonda? 800 mg and 177Lu-PSMA-617 achieved a PSA response.
SYDNEY, 20 May, 2019: Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) is pleased to announce that A/Professor Louise Emmett will deliver an oral presentation of interim results from the LuPIN trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting. LuPIN is investigating 177Lu-PSMA-617 in combination with Veyonda? in men with late stage metastatic castration-resistant prostate cancer (mCRPC).
For further information please download PDF attached:
Download this document
